Novel route for elimination of brain oxysterols across the blood-brain barrier: conversion into 7α-hydroxy-3-oxo-4-cholestenoic acid

Steve Meaney,1,* Maura Heverin,1,* Ute Panzenboeck,† Lena Ekström,§ Magnus Axelsson, ** Ulla Andersson,* Ulf Diczfalusy,* Irina Pikuleva,†† John Wahren,§§ Wolfgang Sattler,*** and Ingemar Björkhem2,*

Division of Clinical Chemistry* and Division of Clinical Pharmacology,§ Karolinska University Hospital, Huddinge, Sweden; Division of Clinical Chemistry** and Division of Surgical Sciences,§§ Karolinska University Hospital, Solna, Sweden; Department of Pharmacology and Toxicology,†† University of Texas Medical Branch, Galveston, TX; and Institute of Pathophysiology† and Institute of Molecular Biology and Biochemistry, Center of Molecular Medicine,*** Medical University Graz, Graz, Austria

Abstract Recently, we demonstrated a net blood-to-brain passage of the oxysterol 27-hydroxycholesterol corresponding to 4–5 mg/day. As the steady-state levels of this sterol are only 1–2 μg/g brain tissue, we hypothesized that it is metabolized and subsequently eliminated from the brain. To explore this concept, we first measured the capacity of in vitro systems representing the major cell populations found in the brain to metabolize 27-hydroxycholesterol. We show here that 27-hydroxycholesterol is metabolized into the known C27 steroidal acid 7α-hydroxy-3-oxo-4-cholestenoic acid by neuronal cell models only. Using an in vitro model of the blood-brain barrier, we demonstrate that 7α-hydroxy-3-oxo-4-cholestenoic acid is efficiently transferred across monolayers of primary brain microvascular endothelial cells. Finally, we measured the concentration of 7α-hydroxy-3-oxo-4-cholestenoic acid in plasma from the internal jugular vein and brachial artery of healthy volunteers. Calculation of the arteriovenous concentration difference revealed a significant in vivo flux of this steroid from the brain into the circulation in human. Together, these studies identify a novel metabolic route for the elimination of 27-hydroxylated sterols from the brain.

Cholesterol is essential for the correct function of the brain. The necessity to maintain tight control of brain cholesterol levels has led to the evolution of specialized mechanisms for the control of cholesterol levels within the central nervous system. First, the blood-brain barrier prevents the exchange of cholesterol between the brain and plasma. Conversion of cholesterol to side chain oxidized oxysterols, however, facilitates its passage across the blood-brain barrier, and it is well documented that the most important mechanism by which the brain eliminates excess cholesterol is via the formation and secretion of 24S-hydroxycholesterol (for reviews, see Refs. 1, 2).

Using established physiological methods to investigate blood-to-brain transport, we recently made the surprising discovery that 27-hydroxycholesterol passes from the circulation into the central nervous system (3). This finding is in agreement with our previous observations that labeled 27-hydroxycholesterol passed from the circulation into cerebrospinal fluid in a healthy volunteer and that the levels of 27-hydroxycholesterol in the circulation and the cerebrospinal fluid were correlated (4). However, despite the fact that 4–5 mg of 27-hydroxycholesterol passes into the brain each day, its levels are only 1–2 μg/g (5). Absence of a functional sterol 27-hydroxylase, which occurs in cebrotendinous xanthomatosi, results in the accumulation of cholesterol and cholestanol in the form of brain xanthomas (6).

The discrepancy between the expected and observed levels of intracerebral 27-hydroxycholesterol suggested to us that this oxysterol must be further metabolized. It is well known that as part of bile acid synthesis 27-hydroxycho-
lesterol may be metabolized into a number of C27 steroidal acids, which are also present at micromolar levels in the plasma (7). Using primary rat astrocytes, Zhang et al. (8) demonstrated the conversion of radiolabeled 27-hydroxycholesterol to several of these acidic intermediates. However, only trace amounts of 7α-hydroxy-3-oxo-4-cholestenolic acid, the terminal metabolite in this pathway, were found. To date, only one other biological compartment has been shown to contain appreciable amounts of this steroidal acid; Nagata et al. (9) showed that subdural hematomas contain more than five times as much 7α-hydroxy-3-oxo-4-cholestenolic acid as the general circulation. In addition, there was an absence of this steroid in normal cerebrospinal fluid (10).

We hypothesized, based on the available data, that 27-hydroxycholesterol within the CNS is metabolized to a steroidal acid before being eliminated from the brain. Using different in vitro approaches, we show that 27-hydroxycholesterol is metabolized to 7α-hydroxy-3-oxo-4-cholestenolic acid and that this acid can rapidly traverse a model of the blood-brain barrier. Finally, by measuring the concentrations of all of the cholestenolic acids in the internal jugular vein and in the brachial artery of healthy volunteers, we show a net flux of 7α-hydroxy-3-oxo-4-cholestenolic acid from the brain to the circulation. Together, these results are consistent with 7α-hydroxy-3-oxo-4-cholestenolic acid being an important terminal metabolite of 27-hydroxycholesterol present in the brain.

MATERIALS AND METHODS

Materials

All organic solvents used were of gas chromatography or high performance liquid chromatography grade.

Synthesis of labeled steroids

Deuterium-labeled internal standards and unlabeled reference compounds were synthesized as described previously (11). [7β-2H]7α-hydroxy-3-oxo-4-cholestenolic acid was prepared from [7β-2H]7α-hydroxycholesterol (with a specific activity of 100 μCi/mg) via sequential treatment with bacterial cholesterol oxidase and recombinant human sterol 27-hydroxylase, with a 40% yield of the desired product. The radiolabeled product was purified by HPLC using a YMC-Pack ODS-A 250 × 4.6 mm inner diameter S-5 μm, 120A column and a mobile phase of 15 mM potassium phosphate, pH 5.4, buffer-methanol (1:3, v/v). The purified product was dried under vacuum, and redissolved in 0.5 ml of chloroform. This material was then applied to a Bond-Elut column (Varian) previously conditioned with 4 ml of hexane and allowed to enter the column matrix under gravity. Neutral steroids were eluted with 4 ml of acetic acid-diethyl ether (1:50, v/v). The organic phase was removed and the column further washed with 4 ml of chloroform-methanol (2:1, v/v) in a separatory funnel. The organic phase was removed, dried under vacuum, and redissolved in 0.5 ml of chloroform. In no case did the vehicle exceed 0.5% of the total medium. Triplicate 100 mm dishes were incubated for 24, 48, and 72 h. After the appropriate incubation period, cell medium was aspirated from the cells and immediately frozen at −20°C until required.

Expression profiling of different cell preparations

Total RNA was extracted from dishes of the cells described above treated with vehicle or 27-hydroxycholesterol (27-OHC) using Trizol® (Invitrogen, Carlsbad, CA) according to the manufacturer’s instructions. Reverse transcriptase-PCR was performed with Superscript™ One-Step RT-PCR with Platinum® Taq (Invitrogen) with gene-specific primers and 250 ng of total RNA. Primers, product sizes, and annealing temperatures (Ta) were as follows. For CYP27A1 (223 bp), sense (5' AACGGAACCT- TGGATGGTTG-3') and antisense (5' GTTCTGAATGCTGC- CACT-3'); Ta = 57.2°C. For oxysterol 7α-hydroxylase (CYP7B1) (152 bp), sense (5' GTCTCTAGATGGCTGCCA-3') and antisense (5' CATTGCTGGTTCAAGTCT-3'); Ta = 52°C. For 3β-hydroxy-C27-sterol dehydrogenase/isomerase (HSDB7) (209 bp), sense (5' TCCAGGGACACCTGATCTG-3') and antisense (5' GTAGCCCTTGACCCCTG-3'); Ta = 57.7°C. Human adult brain total RNA (Clontech, Mountain View, CA) was used as a positive control. The temperature program was per the manufacturer’s instructions, and samples were amplified for either 36 or 38 cycles. Products were run on a 2% agarose gel and visualized with ethidium bromide and an ultraviolet transilluminator.

Incubations with 27-hydroxycholesterol

For metabolic transformation experiments, complete medium was removed from the cells and replaced with serum-free medium containing 20 μg of 27-hydroxycholesterol dissolved in 45% (v/v) 2-hydroxypropyl-β-cyclodextrin and ethanol. No case did the vehicle exceed 0.5% of the total medium. Triplicate 100 mm dishes were incubated for 24, 48, and 72 h. After the appropriate incubation period, cell medium was aspirated from the cells and immediately frozen at −20°C until required.

Analysis of cell medium

Determination of steroid content in the cell medium was performed as described previously (7). Briefly, 300 ng of norcholestenolic acid was added as internal standard to 7.5 ml of cell medium before extraction with 30 ml of chloroform-methanol (2:1, v/v) in a separatory funnel. The organic phase was removed, dried under vacuum, and redissolved in 0.5 ml of chloroform. This material was then applied to a Bond-Elut column (Varian) previously conditioned with 4 ml of n-hexane and allowed to enter the column matrix under gravity. Neutral steroids were eluted with 4 ml of chloroform-isopropanol (2:1, v/v), and acidic steroids were eluted with 4 ml of acetic acid-diethyl ether (1:50, v/v). Each of the fractions was stored under argon at −20°C until required. Derivatization and analysis of these fractions were performed as described previously (7).

Isolation of porcine brain microvascular endothelial cells

Porcine brains were obtained from freshly slaughtered pigs. After removal of the meninges and secretory areas, the gray and white matter of the cerebral cortex were minced and porcine brain microvascular endothelial cells were isolated by sequential enzymatic digestion and centrifugation steps as described (14). Clusters from one brain were seeded in medium A (M199 containing 10% ox serum, 1% penicillin/streptomycin, and 1% gentamycin) on six 75 cm² cell skin collagen-coated flasks (60 μg/ml). After 1 day in vitro, cells were washed with PBS and cultivated in medium B (identical to medium A except lacking gentamycin).

In vitro blood-brain barrier efflux experiments

Cells were seeded on cell skin collagen-coated Transwell inserts on 12-well cell cluster plates at a density of 40,000 cells/cm².
in medium B. After 3 days, induction of tight junctions was initiated via overnight incubation in DMEM/Ham's F12 supplemented with 150 nM hydrocortisone, 1% penicillin/streptomycin, and 0.25% glutamine. The integrity of the monolayer was ascertained by measuring the transendothelial electrical resistance using an Endohm electrode. For efflux experiments, \[^{3}H\]7a-hydroxy-3-oxo-4-cholestenolic, \[^{3}H\]24S-hydroxycholesterol, or \[^{3}H\]cholesterol was added to the basolateral compartment, together with a defined amount of unlabeled material to maintain a constant sterol concentration (0.5 µg/1.5 ml) in the basolateral compartment. Fatty acid-free BSA (0.5 and 1 mg/ml) or human serum (1%, v/v) was added as sterol acceptor to the apical compartment. At the indicated time points, 100 µl of the apical medium was removed for the determination of transferred radioactivity and replaced with fresh medium. At the end of the incubations, transendothelial electrical resistances were measured, cells were washed with PBS, transferred to a new 12-well chamber, and lysed in 0.3 N NaOH by overnight incubation on an orbital shaker at 4°C, and the cell-associated radioactivity was measured.

**Catheterization experiments**

Ten healthy males, mean age 29 years (range, 21–38 years), were recruited for this study. Because of analytical problems and lack of material, only 9 of the 10 patients could be included in the study. After an overnight fast, blood samples were taken simultaneously from two catheters inserted percutaneously. One Courand catheter was inserted at the level of the inguinal ligament, and the tip was advanced under fluoroscopic control to the internal jugular vein at the base of the skull. A second thin Teflon catheter was introduced into the brachial artery in the antecubital fossa.

**Measurement of plasma sterols**

Plasma levels of the steroidal acids known to be formed from 27-hydroxycholesterol were measured essentially as described by Axelson, Mörk, and Sjövall (7). Norcholestenolic acid was used as an internal standard, and the samples were analyzed as methyl esters-trimethylsilyl ethers by combined gas chromatography-mass spectrometry using the selected ion-monitoring mode (7). The following ions were monitored: \(m/z\) 488 (norcholestenolic acid), \(m/z\) 500 (3β,7α-dihydroxy-5-cholestenolic acid), \(m/z\) 412 (3β-hydroxy-5-cholestenolic acid), and \(m/z\) 426 (7α-hydroxy-3-oxo-4-cholestenolic acid). To quantify the other acids using this standard curve, compensation factors of 0.33 and 0.78 were applied to correct for the intensity of the \(m/z\) 412 ion of 3β-hydroxy-5-cholestenolic acid and for the intensity of the \(m/z\) 426 ion of 7α-hydroxy-3-oxo-4-cholestenolic acid relative to the \(m/z\) 412 ion of 3β-hydroxy-5-cholestenolic acid and the \(m/z\) 412 ion of 3β-hydroxy-3-oxo-4-cholestenolic acid relative to the \(m/z\) 412 ion of 3β-hydroxy-3-oxo-4-cholestenolic acid, respectively. In addition, the neutral steroid 7α-hydroxy-4-cholest-3-one, another possible precursor, was measured by HPLC using an ultraviolet detector. Finally, cholesterol and albumin levels were measured using an enzymatic colorimetric assay and a colorimetric assay, respectively, on the Roche/Hitachi modular routine analyzer.

**Statistical evaluations**

Results are presented as means ± SEM. In our evaluation of the metabolite profiling, we used the one-tailed Student’s t-test to evaluate the significance of differences, in accordance with our hypothesis of a net efflux of some metabolite of 27-hydroxycholesterol from the brain. \(P < 0.05\) and \(P < 0.01\) were considered significant.

**Ethical aspects**

All subjects were informed of the nature, purpose, and possible risks of the study before giving their voluntary consent to participate. The study protocol was reviewed and approved by the institutional ethics committee.

**RESULTS**

**Cell-specific metabolism of 27-hydroxycholesterol**

As a first step in the investigation of the metabolism of 27-hydroxycholesterol within the human brain, we screened several commonly used cell systems for suitability as models of neurons, astrocytes, and microglia. RT-PCR-based profiling of enzymes known to be involved in the metabolism of 27-hydroxycholesterol (i.e., CYP27A1, CYP7B1, and HSD3B7) in different cell types revealed that SH-SH5Y, D-384, and CHME-3 cells had expression profiles consistent with those described in vivo (15–17). Notably, only SH-SY5Y neuroblastoma cells expressed CYP7B1. Thus, we considered these cell systems suitable models for the exploration of the metabolism of 27-hydroxycholesterol.

Incubation of each of the cell types with 27-hydroxycholesterol led to a time-dependent formation of both 3β-hydroxy-5-cholestenolic and 3β,7α-dihydroxy-5-cholestenolic acids (Fig. 1B). However, only SH-SH5Y cells were capable of metabolizing 27-hydroxycholesterol to 7α-hydroxy-3-oxo-4-cholestenolic acid, albeit at amounts close to the limits of detection of our gas chromatography-mass spectrometry technique (results not shown). In parallel experiments, trace amounts (50 ng) of radiolabeled 27-hydroxycholesterol were incubated with SH-SY5Y cells. Under these conditions, which may be regarded as considerably more physiological than the saturating conditions described previously, almost 6% of the 27-hydroxycholesterol was converted to 7α-hydroxy-3-oxo-4-cholestenolic acid (Fig. 1C). The conversion into the immediate precursor, 7α-hydroxy-cholestenolic acid, was ∼50%. In a separate experiment, D-384 and CHME-3 cells were incubated with a mixture of 7α- and 7β-hydroxycholestenolic acid. Under these conditions, D-384 cells were able to metabolize ∼50% of the added material to 7α-hydroxy-3-oxo-4-cholestenolic acid (results not shown).

**Efflux of 7α-hydroxy-3-oxo-4-cholestenolic acid across porcine brain microvascular endothelial cell monolayers**

To gain some insight into whether 7α-hydroxy-3-oxo-4-cholestenolic acid is a viable transport form of 27-hydroxycholesterol, we used an established in vitro model of the blood-brain barrier consisting of high-resistance monolayers of porcine cerebral microvascular endothelial cells (14). We demonstrated that the basolateral-to-apical transfer of radiolabeled 7α-hydroxy-3-oxo-4-cholestenolic acid was apparently nonsaturable and time-dependent and occurred in both the presence and absence of serum proteins (Fig. 2A). Importantly, this transfer was significantly faster than that of 24S-hydroxycholesterol (Fig. 2B), an oxysterol that is well known to efficiently traverse the
Fig. 1. Intracerebral routes for the formation of C27 steroidal acids. A: Expression of genes involved in the formation of 7α-hydroxy-3-oxo-4-cholestenoic acid (7α-OH-4-CA) in cell culture systems. Although human brain contained substantial amounts of each message, only SH-SY5Y cells expressed the complete metabolic pathway of the genes required for the formation of 7α-OH-4-CA. These expression profiles are consistent with those described previously. B: Incubation of SH-SY5Y cells with saturating concentrations of 27-hydroxycholesterol (27-OHC) resulted in a significant time-dependent production of cholestenoic acid (CA) and 7α-hydroxy-cholestenoic acid (7α-OH-CA). In addition, there was also a very low formation of 7α-OH-4-CA. In contrast, incubations of D-384 and CHME-3 cells under identical conditions resulted in the formation of cholestenoic acid only, with little or no formation of other C27 steroidal acids. Values shown are means ± SEM. C: Metabolism of [3H]27-OHC by SH-SY5Y cells. The radio-HPLC chromatogram shows the conversion of [3H]27-OHC to 7α-OH-CA (~45%) and 7α-OH-4-CA (~6%).
blood-brain barrier in vivo (1). As expected, there was almost no measurable transport of cholesterol across the cell system. Addition of either serum or fatty acid-free albumin significantly stimulated the rate of transfer. Retention of the label by the cells was negligible. B, C: Comparative transfer of $[^3H]$cholesterol, $[^3H]24S$-OHC, and $[^3H]7\alpha$-OH-4-CA across porcine brain microvascular endothelial cell monolayers. Addition of serum to the apical compartment led to a 2-fold increase in $7\alpha$-OH-4-CA transfer, whereas 24S-hydroxycholesterol (24S-OHC) and cholesterol were only marginally stimulated (C). Transfer of radiolabeled steroids at each time point was estimated as a percentage of the total (medium + cells) radioactivity present. Values represent means ± SD of three experiments. * $P < 0.05$, ** $P < 0.01$.

In the experiments shown in Fig. 2A–C, we also measured the percentage of cell-associated radioactivity. In all of these experiments, except those with 24$S$-hydroxycholesterol, the percentage of cell-associated radioactivity varied between 0.4% and 1.2% of the radioactivity added to the basolateral compartment. In the experiments with 24$S$hydroxycholesterol, however, the corresponding figures varied between 3% and 4% of the added radioactivity.

**Arteriovenous differences of plasma sterols**

To investigate the possibility that any of the steroidal acids shown in Fig. 3 and identified in the cell experiments are excreted from the human brain, we used an established technique based on sampling plasma from the jugular vein and the brachial artery of healthy volunteers.
Analysis by GC-MS revealed that all of the major metabolites of 27-hydroxycholesterol known to be present in the general circulation were also present in the arterial and jugular plasma. Calculation of the net transfer of each sterol revealed that only one compound was found at significantly higher levels in the venous circulation ($P < 0.03$), which is equivalent to an efflux from the brain (Table 1). No significant concentration difference was found for any other C27 steroidal acid or for the terminal metabolites of 27-hydroxycholesterol (i.e., bile acids). Moreover, despite intensive efforts, only trace amounts of possible hydroxylated metabolites of 27-hydroxycholesterol (i.e., 24,27-dihydroxycholesterol and 7a,27-dihydroxycholesterol) were found, indicating that these are unlikely to be participants in the elimination of 27-hydroxycholesterol from the brain (results not shown).

As these steroidal acids are likely to be transported bound to albumin, we also measured albumin concentrations in the arterial and venous plasma. To our surprise, we observed a small but significant difference in albumin concentrations between the internal jugular vein and the artery. To the best of our knowledge, a decrease in albumin concentrations was associated with an increase in the concentration of 7a-hydroxycholesterol in the arterial plasma, which is consistent with the efflux of this sterol from the brain. This finding suggests that 7a-hydroxycholesterol is actively transported across the blood-brain barrier, possibly through a specific transport mechanism.

### Table 1. Absolute and albumin-related concentrations of 27-oxygenated steroids in brachial artery and jugular vein

| Steroid | Brachial Artery | Jugular Vein | Arteriovenous Difference | $P$  |
|---------|----------------|--------------|--------------------------|------|
| **Analyte concentration** | | | | |
| Cholesterol (mg/ml) | 1.56 ± 0.04 | 1.53 ± 0.04 | 0.02 ± 0.02 | NS  |
| Albumin (mg/ml) | 42.7 ± 1.15 | 41.6 ± 0.95 | 1.1 ± 0.42 | <0.05 |
| 7a-Hydroxy-4-cholesten-3-one (ng/ml) | 24.4 ± 5.4 | 24.5 ± 5.4 | −0.01 ± 0.83 | NS |
| 3β-Hydroxy-5-cholesten-3-one (ng/ml) | 75.5 ± 5.9 | 74.4 ± 5.5 | 1.1 ± 1.4 | NS |
| 3β,7a-Dihydroxy-5-cholesten-3-one (ng/ml) | 29.5 ± 4.9 | 28.9 ± 4.9 | 0.6 ± 0.7 | NS |
| 7a-Hydroxy-3-oxo-4-cholesten-3-one (ng/ml) | 27.4 ± 3.5 | 30.3 ± 3.1 | −2.8 ± 1.3 | <0.05 |
| **Analyte-albumin ratio** | | | | |
| 3β-Hydroxy-5-cholesten-3-one (ng/mg) | 1.79 ± 0.17 | 1.81 ± 0.16 | −0.02 ± 0.03 | NS |
| 3β,7a-Dihydroxy-5-cholesten-3-one (ng/mg) | 0.69 ± 0.12 | 0.69 ± 0.12 | −0.004 ± 0.02 | NS |
| 7a-Hydroxy-3-oxo-4-cholesten-3-one (ng/mg) | 0.65 ± 0.09 | 0.73 ± 0.08 | −0.08 ± 0.03 | <0.05 |

Values shown are means ± SEM ($n = 9$), except for 7a-hydroxy-4-cholesten-3-one, which $n = 6$. Oxysterols and the blood-brain barrier
min concentration in the jugular vein has not been reported previously. Correction of the levels described above for the C27 steroidal acids for changes in albumin levels did not alter the pattern revealed by the absolute concentrations: 7α-hydroxy-3-oxo-4-cholestenoic acid remained the only metabolite present at significantly greater concentrations \((P = 0.015)\) in the venous circulation. Based on these results, the flux of 7α-hydroxy-3-oxo-4-cholestenoic acid from the brain was calculated to be \(\sim 2 \text{ mg/24 h}\).

**DISCUSSION**

It is well established that conversion of cholesterol into 24S-hydroxycholesterol is of importance for cholesterol homeostasis in the brain (for review, see Ref. 1). However, this mechanism appears to be responsible for the removal of only two-thirds of newly synthesized cholesterol in rodents (19, 20). To compensate for continuing cholesterol synthesis in the brain, additional mechanisms are likely to exist. The occurrence of brain xanthoma in patients with cerebrotendinous xanthomatosis is consistent with the possibility that sterol 27-hydroxylase is involved in such an additional removal mechanism.

It is well known that sterol 27-hydroxylase is involved in cholesterol elimination in cells such as macrophages and endothelial cells. We have shown previously that there is a centripetal flux of 27-oxygenated steroids to the liver, where they are taken up and integrated into bile acid synthesis. However, uptake of 7α-hydroxy-3-oxo-4-cholestenonic acid is extremely efficient, with an apparent extraction of \(>40\%\) in a single pass (21). The present results show that secretion of 7α-hydroxy-3-oxo-4-cholestenonic acid by the brain is also highly efficient, implying that this steroid is well adapted to fulfill a role as a transport form for sterols.

This contention is supported by the present results using porcine brain microvascular endothelial cells. Transfer of 7α-hydroxy-3-oxo-4-cholestenonic acid proceeds by an apparently nonsaturable mechanism. Interestingly, the rate of transfer was considerably greater than that of 24S-

---

**Fig. 4.** Crosstalk of oxysterols over the blood-brain barrier (BBB) in humans. The efficient blood-brain barrier restricts the movement of cholesterol (Chol.) into and out of the brain. However, side chain oxidized oxysterols are capable of crossing this barrier. 24S-Hydroxycholesterol can exit the brain and serve as an excretory form of brain cholesterol, whereas 27-hydroxycholesterol may pass from the general circulation into the brain. Highly efficient systems exist to rapidly metabolize 27-hydroxylated sterols present in the brain to the major metabolite 7α-hydroxy-3-oxo-4-cholestenonic acid. CYP46A1, cholesterol 24S-hydroxylase; CYP7B1, oxysterol 7α-hydroxylase; CYP27A1, sterol 27-hydroxylase; HSD3B7, 3β-hydroxy-C27-sterol dehydrogenase/isomerase.
to an increased flux of 27-hydroxycholesterol is lost in the brain of Alzheimer’s patients. In any case, it is evident that the present pathway for the elimination of 27-hydroxylated sterols must be important in connection with the increased amounts of 27-hydroxycholesterol in the Alzheimer’s brain.

To summarize, we have identified a new mechanism for the elimination of 27-hydroxylated sterols, and potentially also cholesterol, from the brain. The essential features of this mechanism are depicted in Fig. 4. According to the present data, this new pathway corresponds to a steroid flux that is about one-third of that of 24S-hydroxycholesterol. However, once 7α-hydroxy-3-oxo-4-cholestenoic acid has been formed, it is eliminated very efficiently, and the importance of the conversion may be greater under pathological conditions. It is tempting to suggest that the lack of this mechanism in patients with cerebrotendinous xanthomatosis may be part of the explanation for the accumulation of brain xanthomas in this disease.

This work was supported by the Swedish Science Council, the Heart-Lung Foundation, Brain Power, the Foundations “Gamla Tjänarinnor,” Thuring, Lars Hiertas, and Stohnes, and the Austrian Science Fund (P17474-B0), National Institutes of Health Grants GM-62882 and AG-024336, and in part by Pfizer. The gift of the CHME-3 microglial cell line from Prof. M. Tardieu (Université Paris Sud, France) is gratefully acknowledged.

REFERENCES

1. Dietschy, J. M., and S. D. Turley. 2004. Thematic review series: brain lipids. Cholesterol metabolism in the central nervous system during early development and in the mature animal. J. Lipid Res. 45: 1375–1397.
2. Björkhem, I., and S. Meaney. 2004. Brain cholesterol: long secret life behind a barrier. Arterioscler. Thromb. Vasc. Biol. 24: 806–815.
3. Heverin, M., S. Meaney, D. Lütjohann, U. Diczfalusy, J. Wahren, and I. Björkhem. 2005. Crossing the barrier: net flux of 27-hydroxycholesterol into the human brain. J. Lipid Res. 46: 1047–1052.
4. Leoni, V., T. Masterman, P. Patel, S. Meaney, U. Diczfalusy, and I. Björkhem. 2003. Side chain oxidized oxysterols in cerebrospinal fluid and the integrity of blood-brain and blood-cerebrospinal fluid barriers. J. Lipid Res. 44: 793–799.
5. Heverin, M., N. Bogdanovic, D. Lütjohann, T. Bayer, I. Pikuleva, L. Bretillon, U. Diczfalusy, B. Winblad, and I. Björkhem. 2004. Changes in the levels of cerebral and extracerebral sterols in the brain of patients with Alzheimer’s disease. J. Lipid Res. 45: 186–193.
6. Björkhem, I., K. Muri Boberg, and E. Leitersdorf. 2001. The Metabolic and Molecular Bases of Inherited Disease. 8th edition. McGraw Hill, New York.
7. Axelsson, M., B. Mörk, and J. Sjövall. 1988. Occurrence of 3β-hydroxy-5-cholestenoic acid, 3β,7α-dihydroxy-5-cholestanic acid, and 7α-hydroxy-3-oxo-4-cholestenic acid as normal constituents in human blood. J. Lipid Res. 29: 629–641.
8. Zhang, J., Y. Akwa, M. el-Etr, E. E. Baulieu, and J. Sjövall. 1997. Metabolism of 27-, 25- and 24-hydroxycholesterol in rat glial cells and neurons. Biochem. J. 322: 173–184.
9. Nagata, K., K. Takakura, T. Asano, Y. Seyama, H. Hirota, N. Shigematsu, I. Shima, T. Kasama, and T. Shimizu. 1992. Identification of 7α-hydroxy-3-oxo-4-cholestenic acid in cerebral spinal fluid after subarachnoid hemorrhage. Neuro. Med. Chir. (Tokyo). 35: 294–297.
10. Björkhem, I. 1969. On the mechanism of the enzymatic conversion of cholest-5-ene-3β,7α-diol into 7α-hydroxycholesterol-4-ene-3-one. Eur. J. Biochem. 8: 357–354.
11. Janabi, N., S. Peudenier, B. Heron, K. H. Ng, and M. Tardieu. 1995. Establishment of human microglial cell lines after transfection of primary cultures of embryonic microglial cells with the SV40 large T antigen. Neurosci. Lett. 195: 105–108.
12. Balmain, A. J. S. G. Ball, R. I. Freshney, D. I. Graham, H. B. McNamee, and P. F. Vaughan. 1986. D-1 dopaminergic and beta-adrenergic stimulation of adenylate cyclase in a clone derived from the human astrocyoma cell line G-CCM. J. Neurochem. 47: 713–719.
13. Balmforth, A. J., S. G. Ball, R. I. Freshney, D. I. Graham, H. B. McNamee, and P. F. Vaughan. 1986. D-1 dopaminergic and beta-adrenergic stimulation of adenylate cyclase in a clone derived from the human astrocyoma cell line G-CCM. J. Neurochem. 47: 713–719.
14. Balmforth, A. J., S. G. Ball, R. I. Freshney, D. I. Graham, H. B. McNamee, and P. F. Vaughan. 1986. D-1 dopaminergic and beta-adrenergic stimulation of adenylate cyclase in a clone derived from the human astrocyoma cell line G-CCM. J. Neurochem. 47: 713–719.
15. Jellinck, P. H., M. Kaufmann, A. Gottfried-Blackmore, G. Croft, V. Byford, B. S. McEwen, G. Jones, and K. Bulloch. 2006. Dehydroepiandrosterone (DHEA) metabolism in the brain: identification by liquid chromatography/mass spectrometry of the delta-4-isomer of DHEA and related steroids formed from androstenedione by mouse BV2 microglia. J. Steroid Biochem. Mol. Biol. 98: 41–47.
16. Stolzel, S., M. Watzka, D. Lütjohann, P. Mäkola, A. Nassen, V. H. Hans, H. Glusmann, A. Reissinger, M. Ludwig, L. Siekmann, et al. 2002. Characterization of the dehydroepiandrosterone (DHEA) metabolism via oxysterol 7α-hydroxylase and 17-ketosteroid reductase activity in the human brain. J. Neurochem. 83: 713–726.
17. Trap, C., F. Nato, S. Chabot, S. B. Kim, P. Lafaye, and R. Morfin. 2005. Immunohistochemical detection of the human cytochrome P450B1: production of a monoclonal antibody after cDNA immunization. J. Neuroimmunol. 159: 41–47.
18. Babiker, A., and U. Diczfalusy. 1998. Transport of side-chain oxidized oxysterols in the human circulation. Biochim. Biophys. Acta. 1392: 333–339.
19. Björkhem, I., D. Lütjohann, O. Breuer, A. Sakinis, and A. Wennmalm. 1997. Importance of a novel oxidative mechanism for elimination of brain cholesterol. Turnover of cholesterol and 24(S)-hydroxycholesterol in rat brain as measured with 13C2-oxysterols in vivo and in vitro. J. Biol. Chem. 272: 30178–30184.
20. Lund, E. G., C. Xie, T. Kotti, S. D. Turley, J. M. Dietschy, and D. W. Russell. 2003. Knockout of the cholesterol 24-hydroxylase gene in mice reveals a brain-specific mechanism of cholesterol turnover. J. Biol. Chem. 278: 22980–22988.
21. Lund, E., O. Andersson, J. Zhang, A. Babiker, G. Ahlborg, U. Diczfalusy, K. Einarsso, J. Sjövall, and I. Björkhem. 1996. Importance of a novel oxidative mechanism for elimination of intracellular cholesterol in humans. Arterioscler. Thromb. Vasc. Biol. 16: 208–212.
22. Brown, J., S. Theider, S. Silberman, D. Magnuson, N. Gottardi-Littell, J. M. Lee, D. Yager, J. Crowley, K. Sambamurti, M. M. Rahman, et al. 2004. Differential expression of cholesterol hydroxylases in Alzheimer’s disease. J. Biol. Chem. 279: 34674–34681.
23. Björkhem, I., M. Heverin, V. Leoni, S. Meaney, and U. Diczfalusy. 2006. Oxysterols and Alzheimer’s disease. Acta Neurol. Scand. Suppl. 185: 43–49.
24. Vau, J. L., S. Rasmusson, R. Andrew, M. Graham, J. Noble, T. Olsson, E. Fuchs, R. Lathe, and J. R. Seckl. 2003. Dehydroepiandrosterone 7-hydroxylase CYP7B: predominant expression in primate hippocampus and reduced expression in Alzheimer’s disease. Neurosci.ence. 121: 307–314.
25. Schumacher, M., S. Weil-Engerer, P. Liere, F. Robert, R. J. Franklin, L. M. Garcia-Segura, J. J. Lambert, W. Mayo, R. C. Melcangi, A. Parducz, et al. 2003. Steroid hormones and neurosteroids in normal and pathological aging of the nervous system. Prog. Neurobiol. 71: 3–29.